The GRIK2 gene (formerly known as GLUR6 or GluK2) encodes the GluK2 subunit of the kainate family of ionotropic glutamate receptors. Kainate receptors represent a distinct class of glutamate-gated ion channels that play critical roles in synaptic transmission, neuronal excitability, and synaptic plasticity throughout the central nervous system. Unlike AMPA and NMDA receptors, kainate receptors exhibit unique pharmacological properties, slow kinetics, and are expressed both pre- and post-synaptically where they modulate neurotransmitter release and cellular signaling pathways[1][2].
The GRIK2 gene is located on chromosome 6q16.3 and encodes a protein of approximately 906 amino acids. The GluK2 subunit can form homomeric channels or heteromeric channels when co-assembled with other kainate receptor subunits (GluK1, GluK3, GluK4, or GluK5), creating a diverse repertoire of receptor configurations with distinct pharmacological and physiological properties. Mutations in GRIK2 have been implicated in neurodevelopmental disorders including autism spectrum disorder (ASD) and intellectual disability, while altered GRIK2 expression and function are observed in Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS)[3][4].
| Property | Value |
|---|---|
| Gene Symbol | GRIK2 |
| Full Name | Glutamate Ionotropic Receptor Kainate Type Subunit 2 |
| Chromosomal Location | 6q16.3 |
| NCBI Gene ID | 2899 |
| OMIM ID | 138244 |
| Ensembl ID | ENSG00000164418 |
| UniProt ID | Q16478 |
| Protein Name | Glutamate receptor 6 (GluK2) |
| Protein Class | Ionotropic glutamate receptor (kainate type) |
Like other ionotropic glutamate receptors, GluK2 adopts a modular structure comprising four distinct domains that transduce ligand binding into ion channel opening:
Extracellular N-terminal domain (NTD): Controls receptor assembly, trafficking, and contributes to allosteric modulation; contains the kainate-binding domain
Ligand-binding domain (LBD): Binds glutamate and selective agonists (kainic acid, ATPA); undergoes closure upon agonist binding that drives channel opening
Transmembrane domain (TMD): Forms the ion channel pore, with four transmembrane helices (M1-M4); the channel gate is located at M3
C-terminal intracellular domain (CTD): Contains sites for phosphorylation, ubiquitination, and protein-protein interactions that regulate trafficking and signaling
The subunit composition of kainate receptors dramatically influences their properties. GRIK2 can form functional homomeric receptors (GluK2/GluK2) and heteromeric receptors with other subunits, creating receptors with distinct single-channel conductances, pharmacology, and trafficking characteristics[5][6].
GRIK2 undergoes RNA editing at multiple sites, analogous to AMPA receptor subunits:
These editing events alter the biophysical properties of kainate receptors, including single-channel conductance, calcium permeability, and desensitization kinetics. The Q/R site editing in particular reduces calcium permeability, similar to its effect in AMPA receptors[7][8].
Kainate receptors, including those containing GluK2 subunits, are prominently located on presynaptic terminals where they regulate neurotransmitter release[9]:
The presynaptic location of kainate receptors makes them uniquely positioned to regulate circuit function through modulation of both excitatory and inhibitory transmission.
Postsynaptic kainate receptors mediate slow excitatory postsynaptic potentials (EPSPs) and contribute to synaptic integration:
Kainate receptors are intimately involved in various forms of synaptic plasticity[10][11]:
GRIK2 is one of the most consistently implicated glutamate receptor genes in neurodevelopmental disorders[3:1]:
The mechanism likely involves disruption of kainate receptor function during critical periods of brain development, affecting circuit formation and refinement.
Alzheimer's disease is associated with multiple alterations in GRIK2 expression and function that contribute to synaptic dysfunction[4:1][12]:
Expression changes: Studies of AD brain tissue reveal altered GRIK2 expression in affected regions, including the hippocampus and cortex. The direction and magnitude of changes vary by brain region and disease stage.
Synaptic dysfunction: Kainate receptors are sensitive targets of amyloid-beta (Aβ) oligomer toxicity:
Therapeutic implications: Kainate receptor modulators represent a potential therapeutic approach for AD, though subunit selectivity is critical to avoid unwanted side effects.
Kainate receptors play a complex role in Parkinson's disease and L-DOPA-induced dyskinesias (LID)[13]:
Emerging evidence links GRIK2 dysfunction to ALS pathogenesis[14][15]:
Kainate receptors have historically been associated with epilepsy research since kainic acid itself is a potent seizure-inducing agent[16]:
GRIK2 shows a characteristic pattern of expression throughout the brain:
| Brain Region | Expression Level | Notes |
|---|---|---|
| Hippocampus | High | CA3 region, dentate gyrus |
| Cerebral cortex | High | Layers II-III, V |
| Amygdala | High | Basolateral nucleus |
| Cerebellum | Moderate | Granule cells |
| Striatum | Moderate | Medium spiny neurons |
| Thalamus | Moderate | Relay nuclei |
| Brainstem | Low-moderate | Various nuclei |
The high hippocampal expression suggests important roles in learning and memory, while cortical and striatal expression implicates GRIK2 in higher-order cognitive and motor functions.
Selective pharmacological tools for kainate receptors have been developed[17][18]:
The challenge has been achieving sufficient subunit selectivity while crossing the blood-brain barrier.
Unlike AMPAkines, less development has occurred for kainate receptor positive modulators, though some compounds have been identified that enhance kainate receptor function.
Viral vector-mediated delivery of GRIK2 or modulators of GRIK2 function represents a potential therapeutic strategy for conditions with GRIK2 dysfunction.
Grik2 knockout mice exhibit:
Various genetic models have been developed to study:
The GRIK2 gene encodes the GluK2 kainate receptor subunit, a critical component of excitatory synaptic transmission in the brain. Through its roles in presynaptic modulation, postsynaptic signaling, and synaptic plasticity, GluK2 influences fundamental aspects of neural circuit function. GRIK2 dysfunction is implicated in neurodevelopmental disorders (ASD, intellectual disability), neurodegenerative diseases (AD, PD, ALS), and epilepsy. Understanding the molecular mechanisms by which GRIK2 contributes to these conditions, and developing targeted therapeutic interventions, represents an important frontier in neuroscience research.
Carpenter J, et al. Kainate receptor physiology and pathophysiology. Nature Reviews Neuroscience. 2023. ↩︎
Contractor A, et al. Kainate receptors: From synaptic function to disease. Trends in Neurosciences. 2022. ↩︎
Fernandez M, et al. GRIK2 variants in neurodevelopmental disorders. Molecular Psychiatry. 2023. ↩︎ ↩︎
Gomez R, et al. Kainate receptors in Alzheimer's disease: Synaptic dysfunction and therapeutic potential. Acta Neuropathologica. 2024. ↩︎ ↩︎
Huettner J, et al. The kainate receptor subunits: Structure, function, and pharmacology. Pharmacological Reviews. 2023. ↩︎
Upton AL, et al. Dissecting the subunit composition of kainate receptors. Nature Communications. 2023. ↩︎
Borgesius Z, et al. RNA editing of glutamate receptors in brain development and disease. RNA Biology. 2021. ↩︎
Noguchi J, et al. RNA editing of kainate receptors in neuronal development. Journal of Neuroscience. 2023. ↩︎
Jiang M, et al. Presynaptic kainate receptors regulate neurotransmitter release. Neuron. 2022. ↩︎
Kumar P, et al. Kainate receptors in synaptic plasticity and memory. Progress in Neurobiology. 2023. ↩︎
Lerma J, et al. Kainate receptor desensitization: Molecular mechanisms and therapeutic targeting. Neuropharmacology. 2022. ↩︎
Mendez P, et al. Glutamate receptor trafficking in neurodegenerative diseases. Cellular and Molecular Life Sciences. 2024. ↩︎
Taylor S, et al. Kainate receptors in Parkinson's disease and L-DOPA-induced dyskinesias. Movement Disorders. 2023. ↩︎
Zhang Y, et al. Kainate receptor function in amyotrophic lateral sclerosis. Brain. 2024. ↩︎
Paoletti P, et al. Kainate receptor signaling in neuroprotection and neurodegeneration. Neurobiology of Disease. 2023. ↩︎
Ortiz R, et al. Kainate receptors in the limbic system and epilepsy. Brain Research. 2022. ↩︎
Qian L, et al. Kainate receptors as therapeutic targets in neuropsychiatric disorders. Nature Reviews Drug Discovery. 2024. ↩︎
Yang Y, et al. Targeting kainate receptors for pain relief. Pharmacology & Therapeutics. 2022. ↩︎